Advertise With Us
Subscribe to Newsletter
IB-Logo

[email protected]

  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
IB-Logo
Advertise With Us
Subscribe to Newsletter
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather

Ozempic Heart Benefit

Thomas by Thomas
December 9, 2025
in Health
0
Ozempic Heart Benefit

Ozempic’s semaglutide has affirmed profound heart protections in 2025’s landmark studies, slashing major adverse cardiovascular events (MACE)—heart attacks, strokes, deaths—by 20-23% regardless of weight loss, expanding its role beyond obesity to universal cardiac guardianship for 7 million diabetics. UCL’s Lancet analysis of SELECT’s 17,604 participants—overweight CVD non-diabetics—reveals 20% MACE risk drop, with waist shrinkage accounting one-third via inflammation curbs, blood pressure dips, and vessel mends.

TUM-Harvard’s Nature Medicine emulates: semaglutide/tirzepatide yield comparable 18% reductions in Medicare T2D cohorts, with Ozempic edging dulaglutide 23% in REACH’s head-to-head—first real-world GLP-1 showdown at EASD 2025. Mass General’s JACC substudies affirm: 20% all-cause/CV/non-CV mortality cuts, including COVID deaths, across sexes; HF events plummet in T2D-CKD via left atrial/ventricular diastolic boosts and right ventricular sizing.

Mechanisms transcend slimming: GLP-1‘s incretin mimicry fosters synaptic plasticity, slashing atrial fibrillation 30% and HF risks in obese/non-obese, per Metabolism’s meta-analysis. EASD’s STEER pits Ozempic 2.4mg against tirzepatide: comparable MACE prevention in overweight CVD sans diabetes. Risks: GI tolerance (25% nausea), yet 85% adherence trumps rivals; $1,300/month costs eye scalability.

As NHS pilots Wegovy’s phased access, Ozempic’s heart halo—beyond 17% Wegovy loss—ushers phenotype pharmacotherapy, halving $100 billion obesity’s CV toll.

RelatedPosts

Drugmakers want intervenor status in 340B rebate lawsuit
Health

Drugmakers Want Intervenor Status in 340B Rebate Lawsuit Against HHS

October 21, 2026
CMS proposes to improve accuracy of Medicare Advantage
Business & Finance

CMS Proposes to Improve Accuracy of Medicare Advantage Directories and Cap PBM Fees

October 21, 2026
Medicare Advantage insurers should expect policy scrutiny
Health

Medicare Advantage Insurers Should Expect Policy Scrutiny Heading Into 2026

October 21, 2026
Netcompany Wins $215 Million Contract for NHS Health Screening
Health

Netcompany Wins $215 Million Contract for NHS Health Screening

September 3, 2026
Nature Conservancy Wins Gabon Nature Finance Backing From Bezos and Waltons
Health

Nature Conservancy Wins Gabon Nature Finance Backing From Bezos and Waltons

August 29, 2026
Tommy John Surgery Saved Baseball Careers. But at What Cost
Health

Tommy John Surgery Saved Baseball Careers. But at What Cost?

August 22, 2026

Facebook

IB-Logo

Latest News & Updates
Premier source for business,
financial news, analysis and insights.

  • Fact Checking Policy
  • Editorial Policy
  • Financial Disclaimer
  • Advertising & Sponsored Content Policy
Advertise With Us
  • About Us
  • Contact Us
  • Privacy Policy

© All Rights Reserved 2026 InvestorBytes.

No Result
View All Result
  • About Us
  • Advertising & Sponsored Content Policy
  • Contact Us
  • Editorial Policy
  • Fact-Checking Policy
  • Financial Disclaimer
  • Main Page
  • Markets
  • Privacy Policy

© 2026 InvestorBytes. All rights reserved.

Advertise With Us

No thanks.

Catch up with InvestorBytes

Your weekly dose of market insights and business news, delivered right to your inbox.

No thanks.